Philipp le Coutre
Medizinische Klinik m.S. Hämatologie und Onkologie
Charité -Universitätsmedizin Berlin
Campus Virchow-Klinikum
Augustenburger Platz 1
Germany
Name/email consistency: high
- Clinical cardiac safety profile of nilotinib. Kim, T.D., le Coutre, P., Schwarz, M., Grille, P., Levitin, M., Fateh-Moghadam, S., Giles, F.J., Dörken, B., Haverkamp, W., Köhncke, C. Haematologica (2012)
- Severe peripheral arterial disease during nilotinib therapy. Le Coutre, P., Rea, D., Abruzzese, E., Dombret, H., Trawinska, M.M., Herndlhofer, S., Dörken, B., Valent, P. J. Natl. Cancer Inst. (2011)
- BCR-ABL positive cells and chronic myeloid leukemia in immune suppressed organ transplant recipients. le Coutre, P., Reinke, P., Neuhaus, R., Trappe, R., Ringel, F., Lalancette, M., Hemmati, P.G., Dörken, B., Daniel, P.T. Eur. J. Haematol. (2010)
- New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia. le Coutre, P., Schwarz, M., Kim, T.D. Clin. Cancer Res. (2010)
- Nilotinib. Quintás-Cardama, A., Kim, T.D., Cataldo, V., le Coutre, P. Recent Results Cancer Res. (2010)
- Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. le Coutre, P., Meisel, H., Hofmann, J., Röcken, C., Vuong, G.L., Neuburger, S., Hemmati, P.G., Dörken, B., Arnold, R. Gut (2009)
- Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. le Coutre, P., Ottmann, O.G., Giles, F., Kim, D.W., Cortes, J., Gattermann, N., Apperley, J.F., Larson, R.A., Abruzzese, E., O'Brien, S.G., Kuliczkowski, K., Hochhaus, A., Mahon, F.X., Saglio, G., Gobbi, M., Kwong, Y.L., Baccarani, M., Hughes, T., Martinelli, G., Radich, J.P., Zheng, M., Shou, Y., Kantarjian, H. Blood (2008)